Intellia Therapeutics, Inc. (NTLA): Price and Financial Metrics
NTLA Price/Volume Stats
Current price | $12.06 | 52-week high | $27.42 |
Prev. close | $11.83 | 52-week low | $5.90 |
Day low | $11.86 | Volume | 3,837,700 |
Day high | $12.55 | Avg. volume | 3,943,601 |
50-day MA | $9.34 | Dividend yield | N/A |
200-day MA | $0.00 | Market Cap | 1.25B |
NTLA Stock Price Chart Interactive Chart >
Intellia Therapeutics, Inc. (NTLA) Company Bio
Intellia Therapeutics a gene editing company, develops therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
NTLA Price Returns
1-mo | 31.09% |
3-mo | 52.27% |
6-mo | 21.33% |
1-year | -51.91% |
3-year | -82.32% |
5-year | -42.46% |
YTD | 3.43% |
2024 | -61.76% |
2023 | -12.61% |
2022 | -70.49% |
2021 | 117.35% |
2020 | 270.82% |
Continue Researching NTLA
Want to see what other sources are saying about Intellia Therapeutics Inc's financials and stock price? Try the links below:Intellia Therapeutics Inc (NTLA) Stock Price | Nasdaq
Intellia Therapeutics Inc (NTLA) Stock Quote, History and News - Yahoo Finance
Intellia Therapeutics Inc (NTLA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...